SCHEDULE: Baillie Gifford Discloses 5.27% Stake in Moderna

Baillie Gifford & Co. has filed an amendment to its Schedule 13G, reporting a 5.27% beneficial ownership stake in Moderna, Inc. as of December 31, 2025.

Summary

• Baillie Gifford & Co, an investment adviser based in the United Kingdom, reported beneficial ownership of 20,580,514 shares of Moderna, Inc. Common Stock.
• This ownership represents 5.27% of Moderna's outstanding common stock.
• Baillie Gifford & Co holds sole voting power over 20,033,351 shares and sole dispositive power over all 20,580,514 shares.
• The securities are held in the ordinary course of business on behalf of investment advisory clients and not for the purpose of changing or influencing control of Moderna, Inc.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive, reflecting continued institutional confidence in Moderna by a major investment firm. The maintenance of a significant stake suggests a stable long-term outlook from this investor.

Positives

• A significant institutional holding by a reputable investment adviser like Baillie Gifford & Co can signal long-term confidence in Moderna's prospects and management.

Future Outlook

na

Industry Context

StockSavvy.ai notes that the disclosure of a significant institutional stake, such as Baillie Gifford's 5.27% in Moderna, often indicates a long-term investment thesis by a major player in the asset management industry. This can be viewed as a vote of confidence in Moderna's strategic direction and market position within the biotechnology sector, particularly given its focus on mRNA technology.

Comparison to Industry Standards

• A 5.27% stake represents a substantial position for an institutional investor in a company of Moderna's size, indicating a high conviction investment.
• While this filing does not provide performance metrics for direct comparison, the presence of a major institutional investor like Baillie Gifford, known for its long-term growth investing philosophy, aligns with the investment profiles seen in other innovative biotechnology companies.

Stakeholder Impact

• Shareholders may view the continued significant ownership by Baillie Gifford & Co as a positive signal, potentially reinforcing confidence in Moderna's stock.

Key Dates

Recommendation

The filing indicates a significant, stable institutional holding by Baillie Gifford & Co, suggesting continued confidence in Moderna's long-term prospects. While not a new investment, the sustained large position by a respected investor supports a 'hold' recommendation for existing shareholders and suggests a positive underlying sentiment for potential investors, without providing new catalysts for a 'buy' or 'sell' action.

Keywords

Moderna, Baillie Gifford, Institutional Ownership, Schedule 13G, Beneficial Ownership, Investment Adviser, MRNA, Biotechnology, Pharmaceuticals